[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100383511":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":33,"locations":40,"responsibleParty":62,"collaborators":66,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":18,"enrollmentInfo":79,"targetDuration":18,"studyType":82,"phases":83,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"No anticoagulation","EXPERIMENTAL","Participants in this arm will not receive unfractionated heparin during the course of ECMO. They will receive standard venous thromboembolism prophylaxis with subcutaneous enoxaparin or unfractionated heparin",[13],"Drug: Subcutaneous Heparin",{"label":15,"type":16,"description":17,"interventionNames":18},"Anticoagulation, ECMO standard of care","NO_INTERVENTION","Participants in this arm will receive the standard of care anticoagulation with unfractionated heparin during the course of ECMO.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Subcutaneous Heparin","The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin",[9],[26],"Enoxaparin or unfractionated heparin",[28,31],{"name":29,"affiliation":5,"role":30},"Damian Ratano, MD","PRINCIPAL_INVESTIGATOR",{"name":32,"affiliation":5,"role":30},"Eddy Fan, MD, PhD",[34,38],{"name":29,"role":35,"phone":36,"phoneExt":18,"email":37},"CONTACT","+1 416-340-3601","damian.ratano@chuv.ch",{"name":32,"role":35,"phone":36,"phoneExt":18,"email":39},"eddy.fan@uhn.ca",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Toronto General Hospital","RECRUITING","Toronto","Ontario","M5G 2N2","Canada","CA",{"type":50,"coordinates":51},"Point",[52,53],-79.39864,43.70643,{"lat":53,"lon":52},[56,59],{"name":57,"role":35,"phone":58,"phoneExt":18,"email":39},"Eddy Fan, MD-PhD","+ 1 416 340 3601",{"name":60,"role":61,"phone":18,"phoneExt":18,"email":18},"Manuel Tisminestky, MD","SUB_INVESTIGATOR",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Damian Ratano","Principal Investigator",[67],{"name":68,"class":6},"The Physicians' Services Incorporated Foundation","100383511","phase-2-anticoagulation-free-vv-ecmo-for-acute-respiratory-failure-100383511",false,"NCT04273607","Anticoagulation-free VV ECMO for Acute Respiratory Failure","Anticoagulation-free VV ECMO for Acute Respiratory Failure: A Pilot Safety and Feasibility Randomized Clinical Trial","A-FREE ECMO","Inclusion Criteria:\n\n* Adult patient with ARDS on VV-ECMO\n\nExclusion Criteria:\n\n* Contraindication to anticoagulation with UFH (known heparin-induced thrombocytopenia, active hemorrhage, any surgery precluding the use of anticoagulation),\n* Indication for therapeutic anticoagulation (pulmonary embolism or deep vein thrombosis, chronic anticoagulation therapy before ECMO insertion)\n* Low-flow (\\\u003C2 liters\u002Fmin) VV-ECMO (ECCO2R)","ALL","18 Years",{"count":80,"type":81},40,"ESTIMATED","INTERVENTIONAL",[84,85],"PHASE2","PHASE3","Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have assessed this. The aim of this pilot study is to assess safety and feasibility of an \"anticoagulation-free strategy\" for veno-venous ECMO (VV-ECMO) in Acute respiratory distress syndrome (ARDS).",[88],"Extracorporeal Membrane Oxygenation Complication",[90,91,92,93],"Extracorporeal membrane oxygenation","Anticoagulation","Thrombosis","Hemorrhage","2026-01-14",{"date":96,"type":97},"2026-01-16","ACTUAL",{"date":99,"type":97},"2022-09-01",{"date":101,"type":81},"2027-01-30",{"name":64,"class":6},1]